Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Common Equity: 2017-2024

Historic Common Equity for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $675.3 million.

  • Protagonist Therapeutics' Common Equity rose 21.34% to $645.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.4 million, marking a year-over-year increase of 21.34%. This contributed to the annual value of $675.3 million for FY2024, which is 100.58% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Common Equity stood at $675.3 million for FY2024, which was up 100.58% from $336.7 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Common Equity ranged from a high of $675.3 million in FY2024 and a low of $215.6 million during FY2022.
  • For the 3-year period, Protagonist Therapeutics' Common Equity averaged around $409.2 million, with its median value being $336.7 million (2023).
  • As far as peak fluctuations go, Protagonist Therapeutics' Common Equity soared by 249.66% in 2020, and later declined by 28.14% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Common Equity (Yearly) stood at $279.6 million in 2020, then climbed by 7.30% to $300.0 million in 2021, then dropped by 28.14% to $215.6 million in 2022, then soared by 56.15% to $336.7 million in 2023, then surged by 100.58% to $675.3 million in 2024.